TB500

TB-500 (also known as Thymosin Beta-4 fragment or fequesetide) is a synthetic peptide, typically a shorter fragment (often the actin-binding domain, such as Ac-LKKTETQ) derived from the naturally occurring Thymosin Beta-4 (TB4), a 43-amino-acid protein abundant in most human tissues, especially platelets, wound fluid, and white blood cells.

TB-500 is researched for its role in regulating actin (a key cytoskeletal protein), promoting cell migration, angiogenesis (new blood vessel formation), tissue remodeling, and anti-inflammatory effects—making it a focal point in studies on wound healing, injury recovery, and regeneration.

Potential human benefits (drawn from preclinical animal models showing strong regenerative effects, limited early human observations/trials on related TB4 forms, and widespread anecdotal reports in sports recovery, regenerative medicine, and wellness communities):

• Accelerated injury recovery and tissue repair — users often report faster healing of muscles, tendons, ligaments, and soft tissues; reduced downtime from strains, tears, or overuse injuries; and quicker return to activity or training.
• Reduced inflammation and pain relief — promotes lower swelling and discomfort in injured or inflamed areas, supporting better mobility during recovery.
• Improved flexibility and range of motion — enhances tissue elasticity and remodeling, helping with stiffness, scar tissue reduction, or chronic joint/muscle issues.
• Enhanced wound and skin healing — supports faster closure of wounds, better scar outcomes, and potential skin regeneration or hair growth hints in some contexts.
• Cardiovascular and systemic support — preclinical data suggest benefits for blood vessel repair, circulation improvement, and heart tissue protection; anecdotal reports include general resilience and recovery boosts.
• General regenerative perks — many describe overall faster recovery from workouts, surgeries, or daily wear, with a sense of improved tissue health and vitality.

Human evidence remains limited to small pilots, pharmacokinetic studies (e.g., on TB4 safety/tolerability in wound healing or skin applications), and observations from related compounds—showing good tolerability but lacking large-scale, randomized controlled trials for most claimed benefits. Effects are often self-reported, cumulative, and synergistic with rest, therapy, or other peptides (e.g., BPC-157 in popular "Wolverine" stacks).

Typically researched via subcutaneous injection (dosing protocols vary, often loading then maintenance phases), TB-500 stands out in regenerative peptide research for its systemic actin-modulating action—offering promise for supporting the body's natural repair processes, reducing inflammation, and enhancing recovery across musculoskeletal and soft-tissue contexts.

Important Notice:

This product is intended for research use only.
Not for human or animal use of any kind.
Not a drug. Not approved for clinical or therapeutic use.